ABL receives CE-IVD approval for DeepChek and ViroScore Suite clinical genotyping solutions

Advanced Biological Laboratories (ABL) announced today that DeepChek® and ViroScore® Suite clinical genotyping solutions are now CE-IVD (In Vitro Diagnostics) approved for commercial use in Europe and other countries that recognise CE certification.    

This approval is further validating the use of our next generation sequencing (NGS) downstream analysis software DeepChek®-HIV with several evaluations performed by renowned clinical and virological research centres and the positive results from several international scientific studies. Scientific results from these studies will be presented at upcoming scientific conferences, including the International Workshop on Drug Resistance for HIV and Viral Hepatitis, to be held in Sitges (Spain, 5-9 June, 2012).

"Scientific experts worldwide are increasingly recognising our IT solutions dedicated to HIV clinical genotyping analysis, namely Sanger sequencing within our ViroScore® Suite system and NGS within our DeepChek® system. The CE-IVD approval is in compliance with the latest European directives for medical devices, and positions DeepChek® and ViroScore® Suite as the first IT solutions choices to analyse comprehensive and complex data, thereby pioneering optimised personalised for the treatment of HIV", stated Dr. Chalom B. Sayada, CEO of ABL. "It's also a monumental milestone in our portfolio of medical IT solutions, wherein other growing IVD-segments, such as viral hepatitis, oncology and other chronic diseases, are also being targeted by ABL."